Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence

Share Article

Since her cancer diagnosis in 2013, Dr. Amy Reed and her husband, Dr. Hooman Noorchashm, have led a high-profile public health campaign to ban the use of power morcellators in uterine surgery.

Free Case Review
Our Firm commends Dr. Reed and her husband for their continuing efforts to bring attention to this important public health issue, especially during this difficult time.

Dr. Amy Reed, who together with her husband, Dr. Hooman Noorchashm, has been seeking a ban on the use of power morcellators (http://www.morcellatorlawsuit2015.com) in uterine surgeries, has experienced a recurrence of the cancer that prompted the launch of their public health campaign. The couple told the Philadelphia Inquire earlier this week that the 41-year-old mother of six had recently undergone surgery to remove a small tumor from the bony part in her spine. Dr. Reed had been in remission for about a year after being diagnosed with a rare and aggressive uterine cancer called leiomyosarcoma in late 2013.*

According to the Philadelphia Inquirer, Dr. Reed was initially diagnosed with cancer after undergoing a hysterectomy in October 2013 that involved the use of a power morcellator. Since her diagnosis, she and her husband have launched a petition seeking a ban on such procedures. And in July 2014, they each made an emotional presentation during a U.S. Food & Drug Administration (FDA) hearing convened to examine the cancer risks potentially associated with uterine morcellation.**

“Our Firm commends Dr. Reed and her husband for their continuing efforts to bring attention to this important public health issue, especially during this difficult time. We believe that without their work, federal regulators, the media and others would have never subjected uterine morcellation to the scrutiny it has received since late 2013,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating potential legal claims on behalf of women who allegedly experienced the spread of undiagnosed cancers due to uterine morcellation.

Power Morcellators and Cancer
Power morcellators are used in minimally-invasive hysterectomies and fibroid removal procedures to shred uterine tissue into small pieces so that it can be easily removed through a small abdominal incision. In April 2014, the FDA publically discouraged doctors from using the devices in gynecological surgeries because of their potential to spread and upstage undiagnosed uterine cancers present in fibroids at the time of surgery. Among other things, the agency noted that there is no reliable way to screen for such malignancies prior to surgery, and warned that dissemination of cancer cells via a power morcellator can greatly reduce a woman’s likelihood for long-term survival.***

While the FDA has not banned power morcellators, it did issue a second alert in November 2014 which warned against their use in the majority of women who require hysterectomy and fibroid removals. The agency also asked morcellator manufacturers to add a new black box warning – the strongest possible safety notice – regarding this life-threatening complication to their labels.

Patients whose cancers may have been spread via uterine morcellation could be entitled to file their own morcellator lawsuit against the manufacturer of the device used in their surgery. To learn more about the risks potentially associated with power morcellators, please visit Bernstein Liebhard LLP's website. To obtain a free legal review, please call 800-511-5092.

*philly.com/philly/health/cancer/20150305_Doctor_fighting_to_ban_morcellators_has_cancer_recurrence.html, Philadelphia Inquirer, March 5, 2015
**bostonglobe.com/lifestyle/health-wellness/2014/07/11/agreement-reached-whether-fda-should-ban-hysterectomy-cutting-tool/EkXZaFAUUnT5HZ7DBQvWbM/story.html, Boston Globe, July 11, 2014
***fda.gov/medicaldevices/safety/alertsandnotices/ucm393576.htm, FDA, April 17, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website